Home › RXi Pharmaceuticals Corp (RXII) Downgraded by Zacks Investment Research to "Sell"
 

Keywords :   


RXi Pharmaceuticals Corp (RXII) Downgraded by Zacks Investment Research to "Sell"

2015-12-19 21:28:21| Biotech - Topix.net

According to Zacks, "RXi Pharmaceuticals Corporation is a biotechnology company focused on discovering, developing and commercializing therapies based on its RNAi platform. The Company is developing RXI-109, which is used for the reduction of dermal scarring in planned surgeries, as well as reduces the expression of connective tissue growth factor.

Tags: research sell investment corp

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.05Boeing may face criminal prosecution, US says
15.05Indian spices face heat over global safety concerns
15.05'Corrupt ship inspectors demand our food and cargo'
15.05Taylor Swift Eras Tour to boost UK spending by 1bn, says report
15.05Three ways to win the rental property race
15.05Renters in scrum for homes as listing time slashed
14.05Nu Skin Releases 2023 Social Impact and Sustainability Report
14.05P&G Unveils Plans to Feature Brands During the Olympic and Paralympic Games Paris 2024
More »